Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Non-Current Debt (2010 - 2014)

Gyre Therapeutics (GYRE) reported Non-Current Debt of $142000.0 for Q1 2014, down 84.53% year-over-year from $918000.0 in Q1 2013, and down 49.82% on a QoQ basis from $283000.0 in Q4 2013.

Gyre Therapeutics (GYRE) has 5 years of Non-Current Debt data on file, last reported at $142000.0 in Q1 2014.

  • Quarterly Non-Current Debt fell 84.53% year-over-year to $142000.0 in Q1 2014, while the trailing twelve-month figure through Mar 2014 was $142000.0 (down 84.53% YoY) and the FY2013 annual result came in at $283000.0, down 75.09% from the prior year.
  • Non-Current Debt eased to $142000.0 in Q1 2014 per GYRE's latest filing, from $283000.0 in the prior quarter.
  • Across five years, Non-Current Debt topped out at $2.4 million in Q2 2011 and bottomed at $142000.0 in Q1 2014.
  • The 5-year median for Non-Current Debt is $1.3 million (2010), against an average of $1.3 million.
  • The widest annual swing landed in 2011, when Non-Current Debt surged 47.22%; it then slumped 84.53% in 2014.
  • Tracing GYRE's Non-Current Debt over 5 years: stood at $1.3 million in 2010, then surged by 47.22% to $2.0 million in 2011, then tumbled by 42.8% to $1.1 million in 2012, then sank by 75.09% to $283000.0 in 2013, then slumped by 49.82% to $142000.0 in 2014.
  • Per Business Quant, the three latest GYRE Non-Current Debt figures stand at $142000.0 (Q1 2014), $283000.0 (Q4 2013), and $478000.0 (Q3 2013).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 319.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - 105.94 Mn
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 1.99 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Gyre Therapeutics 532.38 Mn 518.25 Mn 8.38 Mn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2014 142,000.00
Mar 31, 2014 142,000.00
Dec 31, 2013 283,000.00
Dec 31, 2013 283,000.00
Sep 30, 2013 478,000.00
Sep 30, 2013 478,000.00
Jun 30, 2013 699,000.00
Jun 30, 2013 699,000.00
Mar 31, 2013 918,000.00
Mar 31, 2013 918,000.00
Dec 31, 2012 1.14 Mn
Dec 31, 2012 1.14 Mn
Sep 30, 2012 1.35 Mn
Sep 30, 2012 1.35 Mn
Jun 30, 2012 1.56 Mn
Jun 30, 2012 1.56 Mn
Mar 31, 2012 1.78 Mn
Mar 31, 2012 1.78 Mn
Dec 31, 2011 1.99 Mn
Dec 31, 2011 1.99 Mn
Sep 30, 2011 2.20 Mn
Sep 30, 2011 2.20 Mn
Jun 30, 2011 2.44 Mn
Jun 30, 2011 2.44 Mn
Dec 31, 2010 1.35 Mn
Dec 31, 2010 1.35 Mn